Helen Frankenthaler Foundation

oxandrolone drug

Delving into the Latest Updates on Oxandrolone with Synapse

Oxandrolone

Last update 27 Dec 2025

Overview

Basic Info
Drug TypeSmall molecule drug
SynonymsOxandrolone (JAN/USP/INN), NSC-67068, SC-11585 + [4]
TargetAR
Actionagonists
MechanismAR agonists(Androgen Receptor agonists)
Therapeutic AreasNervous System Diseases Other Diseases
Active IndicationOstealgia Weight Loss
Inactive Indication-
Originator OrganizationGemini Laboratories LLC
Active OrganizationGemini Laboratories LLC
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval DateUnited States (21 Jul 1964), Ostealgia Weight Loss
RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular Formula C19H30O3

InChIKey QSLJIVKCVHQPLV-PEMPUTJUSA-N

CAS Registry 53-39-4

Related

27 Clinical Trials associated with Oxandrolone

NCT06974526 / Not yet recruiting Phase 2 IIT

Randomized, Multicenter, Double-blind, Parallel, Placebo-controlled Study to Investigate the Safety and Exploratory Efficacy of the Absorbable Oxandrolone Implant as an Adjuvant Treatment in Rehabilitation Following Anterior Cruciate Ligament (ACL) Surgical Reconstruction (IMOX Study)

Rehabilitation of knee stability and function after anterior cruciate ligament (ACL) reconstruction is slow and costly. The use of anabolic steroids, such as oxandrolone, may aid in the recovery of muscle mass and strength, as well as functional capacity. Oxandrolone, derived from dihydrotestosterone, has high anabolic activity and low androgenic activity (a 13:1 ratio), making it more effective in promoting weight gain with fewer side effects compared to other steroids. Registered by the FDA and previously by ANVISA (National Health Surveillance Agency (Brazil), it is indicated for cases of post-trauma or post-surgery weight loss. The subdermal use of oxandrolone implants is proposed to release the drug directly into the bloodstream, improving efficacy and reducing issues related to oral administration. This study evaluates the safety and tolerability of the absorbable subdermal oxandrolone implant for 24 weeks versus placebo implant in both men and women as an adjuvant treatment during rehabilitation following anterior cruciate ligament (ACL) surgical reconstruction. The serum and pharmacokinetic profile of the oxandrolone implant will be monitored.

Show all

Start Date 16 Jun 2025

Sponsor / Collaborator Science Valley Research Institute

IRCT20200305046700N5 / Recruiting Phase 3 IIT

Investigating the effectiveness of the anabolic steroid oxandrolone on improving the functional outcomes of patients after knee arthroplasty: a double-blind randomized clinical trial.

Start Date 21 Mar 2025

Sponsor / Collaborator Tehran University of Medical Sciences

RBR-2hs894w / Not yet recruiting Phase 2 IIT

Effects of Oxandrolone on clinical outcomes and muscle mass in patients with Septic shock: a randomized clinical trial - ONSET Oxandrolona iN SEpTic patients

Start Date 01 Dec 2023

Sponsor / Collaborator -

100 Clinical Results associated with Oxandrolone

Login to view more data

100 Translational Medicine associated with Oxandrolone

Login to view more data

100 Patents (Medical) associated with Oxandrolone

Login to view more data

751 Literatures (Medical) associated with Oxandrolone

31 Dec 2025·ANNALS OF HUMAN BIOLOGY

Comparative effects of growth hormone, testosterone, and aromatase inhibitors on height gain in children and adolescents with idiopathic short statures: a network meta-analysis

Review

Author: Wang, Xiangyu ; Si, Yingli ; Zhang, Tingting

BACKGROUND: Idiopathic short stature (ISS) is defined as height more than two standard deviations below the mean for age and sex, without an identifiable pathological cause. Pharmacologic options such as growth hormone (GH), testosterone, and aromatase inhibitors (AIs) have been studied for their potential to promote height gain in affected children and adolescents.

AIM: To compare the efficacy of GH, testosterone, and AIs in promoting height gain in children and adolescents with ISS, considering both individual and combination treatments using a network meta-analysis.

SUBJECTS AND METHODS: This meta-analysis was conducted in accordance with the PRISMA 2020 guidelines. A systematic search was performed across PubMed, Embase, Web of Science, Google Scholar, Semantic Scholar, and ResearchRabbit. Eligible studies were selected on the basis of predefined inclusion criteria. Standardised mean differences (SMDs) and 95% confidence intervals (CIs) were calculated. Heterogeneity was assessed via the chi-square test and I 2 index. Publication bias was evaluated via funnel plots and Egger's test.

RESULTS: All the treatment groups (GH, anastrozole, letrozole, AI+GH) demonstrated significantly greater height gains than did the placebo group. Letrozole was associated with the greatest increase in height (SMD = 0.83, 95% CI = 0.38-1.28). No statistically significant differences were observed among the active treatments. Oxandrolone did not significantly differ from the placebo (SMD = 0.52, 95% CI = -0.03-1.07).

CONCLUSION: GH, AIs, and combination therapies improve height in children and adolescents with ISS, with letrozole showing a modest advantage but no clear superiority, highlighting the need for individualised treatment.

Show all

01 Jun 2025·COMPUTERS IN BIOLOGY AND MEDICINE

MiRAGE-DTI: A novel approach for drug–target interaction prediction by integrating drug and target similarity metrics

Article

Author: Abbasian Bajgiran, Yeganeh ; Eskafi, Maryam ; Eslahchi, Changiz ; Hassanali Aragh, Aria ; Moslemi Amirani, Razieh ; Givehchian, Pegah

MOTIVATION: Accurately predicting drug-target interactions (DTIs) is critical for accelerating drug discovery, repositioning, and development. Traditional experimental methods are often expensive and time-consuming, emphasizing the need for efficient computational models to streamline these processes. To address this challenge, we developed MiRAGE-DTI, a novel computational framework that integrates diverse drug and target similarity measures with robust machine learning techniques to achieve superior predictive accuracy.

RESULTS: MiRAGE-DTI introduces a novel framework that integrates structural, functional, and interaction-based features into a unified model. Leveraging the strengths of Random Forest classifiers, MiRAGE-DTI ensures robust and interpretable predictions while addressing challenges such as class imbalance and data variability. Comprehensive evaluations across multiple benchmark datasets, including GPCR, IC, NR, and Enzyme, reveal that MiRAGE-DTI consistently outperforms state-of-the-art algorithms such as DTI-CNN, GCNMDA, MVGCN, MMGCN, GraphCDA, DTINet, and MIDTI. It achieves significant improvements in key metrics such as AUROC, AUPR, and accuracy. To validate its predictions, molecular docking studies were conducted, highlighting strong binding affinities for key drug-target interactions, including Oxandrolone-PGR and Metyrapone-CYP2E1, which demonstrate high therapeutic potential. Beyond predictive accuracy, MiRAGE-DTI has practical implications in drug repositioning and personalized medicine, as well as the potential to streamline preclinical workflows. Its ability to uncover novel drug-target relationships enhances the understanding of molecular mechanisms underlying diseases, paving the way for innovative therapeutic strategies. Furthermore, by predicting off-target interactions and potential side effects, MiRAGE-DTI contributes to improving drug safety profiles and regulatory evaluations.

CONCLUSION: MiRAGE-DTI represents a versatile and powerful tool for advancing drug discovery and development. Its ability to identify novel therapeutic opportunities, repurpose existing drugs, and enable precision medicine highlights its transformative potential in tackling unmet medical needs. The framework's robust performance, validated predictions, and wide-ranging practical applications position MiRAGE-DTI as a critical resource for modern drug discovery.

Show all

01 Jun 2025·Drug Testing and Analysis

Changing trends in anabolic‐androgenic steroid use within Scottish prisons: Detection, prevalence, and quantitation

Article

Author: Harries, Richard L. ; Nic Daéid, Niamh ; Norman, Caitlyn ; Nisbet, Lorna A. ; Reid, Robert

Abstract: Anabolic‐androgenic steroids (AASs) are a subclassification of image performance enhancing drugs (IPEDs). While AAS use is most prevalent among people in athletics, there is also high lifetime prevalence of AAS use among prisoners. This study reports the qualitative detection of AASs in seized samples from the Scottish prisons from 2019–2023. Additionally, methods were developed for the quantitative analysis of AASs using gas chromatography–mass spectrometry (GC–MS) and applied to 61 samples of tablets or powders seized from Scottish prisons between July 2022 and July 2023. Since 2022, there has been an increase in AAS detections in the Scottish prisons. Oxymetholone was the most prevalent AAS, followed by metandienone (methandrostenolone, methandienone), methyltestosterone, oxandrolone, mestanolone (methylandrostanolone), stanozolol, and androstenedione. Multiple AASs were found in 21 samples and 10 samples contained other drugs, including amitriptyline, sertraline, zopiclone, mirtazapine, sildenafil, etizolam, Δ9‐tetrahydrocannabinol, and the synthetic cannabinoid MDMB‐INACA. Most AAS samples were tablets (77.0%), although they were also detected in powders, herbal material, e‐cigarettes, and a fragmented soap bar‐type sample. There was a large variation in the concentration of AASs in the tablets and powders seized from the Scottish prisons, demonstrating AASs are another highly variable component of the polydrug use situation in prisons, the effects of which need to be examined further.

Show all

News (Medical) associated with Oxandrolone
15 Dec 2024

Best Legal Steroids: Effective Bodybuilding Steroid Alternatives for Muscle Growth

Closest thing to real steroids to use for cutting and bulking in the bodybuilding industry SAN FRANCISCO, CA / ACCESSWIRE / December 15, 2024 / For many years, professional and amateur bodybuilders have been drawn to the allure of steroids for muscle growth and strength gains, a trend observed by experienced trainers working closely with athletes over decades.But the risks of anabolic androgenic steroids-legal issues, severe side effects, and long-term damage to your health-just aren't worth it. That's why I've turned my attention to legal steroid alternatives.Legal alternatives to Dianabol and Trenbolone, for example, are designed to give you the same benefits as traditional oral and injectable steroids-more muscle, more strength, and more endurance-but without the downsides.The best part? They're legal and available to buy online in the USA.In this guide, I'll take you through the best bodybuilding steroid alternatives that not only deliver amazing results but also support your overall health and performance. Whether you want to bulk up, get lean, or enhance your athleticism, these legal steroid alternatives have you covered.Best Legal Steroids for Sale Online - IntroHere are the most effective and popular muscle building supplements and legal substitutes to traditional anabolic steroids for sale online in the USA.D-Bal Max (Dianabol)Tren-Max (Trenbolone)Crazy Bulk Stacks (4 x combo)Testo Prime (Testosterone)The listed brands and products can be ordered online and have long money back guarantees. Free delivery to the United States, Canada, UK and Australia.Top-Rated Legal Steroids for Bodybuilding:Here is a more in depth explanation of the most effective steroids for sale that are legally available to buy in the USA. Each produ